Pneumoconiosis is a restrictive and occupational lung disease caused by inhalation of dust. There are a number of different agents that, when inhaled, can potentially cause pneumoconiosis. Organic and inorganic agents are responsible for causing this diseases. According to the Centers for Disease Control and Prevention, in 2013, 260,000 deaths occurred due to pneumoconiosis. Increasing prevalence of pneumoconiosis, increasing smoking population, and rising air pollution have driven the growth of the market. Approximately 75% of non-asbestos pneumoconiosis cases recorded under the IIDB scheme in 2009 were from individuals that are over 65 years. According to the Centers for Disease Control and Prevention, cigarette smoking is the leading cause of death in the United States, accounting for over 480,000 deaths every year. Moreover, increasing geriatric population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, smoking increases the possibility of pneumoconiosis; more than 60% of the global population smokes, this has increased the risk of pneumoconiosis and contributed in the growth of the market. However, side effects associated with the treatment and lack of long term treatment may lead to hinder the growth of the market.
The global pneumoconiosis market analysis by MRFR expected the market to grow at a CAGR of 6.8% during forecast period.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4639
Regional Analysis The Americas dominate the global pneumoconiosis market owing to a large patient population, strong government support for research & development, and high healthcare spending. Smoking increase the risk of causing this disease. According to the Centers for Disease Control and Prevention, in 2015, about 15 in every 100 U.S. adults aged over 18 years smoked cigarettes. Which is estimated around 36.5 million adults in the United States currently smoke cigarettes. Moreover, changing lifestyle and increasing number of smokers has fuelled the growth of the market. Europe has the second leading market in global pneumoconiosis market which is followed by Asia Pacific. Asia Pacific is the fastest growing market for pneumoconiosis. As per statistics, more than half of the china population smoke. China and India contribute a major share in the Asia Pacific pneumoconiosis market. Increasing geriatric population and increasing air pollution in this region have fuelled the growth of the market. The Middle East and Africa contribute the least in the growth of global pneumoconiosis market. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market. Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition. However the growth of the Africa market is high due to the presence of opportunities for the development of the market. Segmentation The global pneumoconiosis market is segmented on the basis of types, causes, therapy, and end users. On the basis of type, the market is segmented into asbestosis, berylliosis, byssinosis, coal workers pneumoconiosis, silicosis, and others. On the basis of cause, the market is categorized into organic dusts, non-organic substances, and others. Organic substances are further segmented into hay, malt, mushrooms, and others. Non organic substances are further segmented into sulphur dioxide, ammonia, nitrogen dioxide, and others. On the basis of therapy, the market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest X-ray, CT scan, and others. Treatment is further classified into mucolytic agent, antibiotic, and others. On the basis of end user, the market is segmented into hospital, clinics, and others. Key Players The key players for the global pneumoconiosis market Abbott (US) Eli Lilly (US), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Novartis (Switzerland), Abbott (US), AstraZeneca (UK), Merck & Co. (U.S.), Pfizer (U.S.), Svizera Healthcare (India), F. Hoffman La Roche AG (Germany), and Bayer Cropscience Ltd. (U.S.). Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/pneumoconiosis-market-4639
Comments